文献速递冠心病心力衰竭与心肌病

REVIVED-BCIS2与STICHES的药物治疗及结局:个体患者数据分析

Medical therapy and outcomes in REVIVED-BCIS2 and STICHES: an individual patient data analysis.
PubMed 文献 · Eur Heart J · 2025-01-01

本研究汇总分析STICHES和REVIVED-BCIS2两项随机试验的个体患者数据,共纳入1912例左室射血分数≤35%的冠心病患者。REVIVED-BCIS2中接受PCI的患者主要终点事件也少于STICHES中接受CABG的患者。

要点

  • REVIVED-BCIS2仅药物治疗者结局优于STICHES仅药物治疗者(校正HR 0.60)。
  • REVIVED-BCIS2中PCI患者结局优于STICHES中CABG患者。
  • 缺血性心肌病人群中CABG、PCI与药物治疗的比较仍需进一步试验。

核心结论

  • REVIVED-BCIS2中接受药物治疗的缺血性心肌病患者结局优于STICHES中接受药物治疗者,无论是否接受CABG。

研究设计与样本

  • 两项多中心随机试验的汇总分析,纳入1912例左室射血分数≤35%的冠心病患者,随机接受CABG(STICHES)或PCI(REVIVED-BCIS2),均接受药物治疗。
  • 主要终点为全因死亡和心力衰竭住院的复合终点,随访完整率98.3%。
  • STICHES中位随访118个月,REVIVED-BCIS2中位随访41个月。

主要发现

  • REVIVED-BCIS2接受PCI者主要终点事件少于STICHES接受CABG者。
  • STICHES接受CABG者的校正结局劣于REVIVED-BCIS2仅药物治疗者。

临床怎么用

  • 对于缺血性心肌病(左室射血分数≤35%)患者,药物治疗基础上血运重建策略的选择需结合个体情况,CABG与PCI的 comparative 效果尚需进一步试验明确。

局限性

  • 两项试验随访时间差异较大(STICHES中位118个月 vs. REVIVED-BCIS2中位41个月),可能影响事件累积比较。
  • 为汇总个体数据分析,非头对头随机比较,存在混杂可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: In the Surgical Treatment for Ischaemic Heart Failure Trial Extension Study (STICHES), coronary artery bypass grafting (CABG) improved outcomes of patients with ischaemic left ventricular dysfunction receiving medical therapy, whereas in the Revascularization for Ischaemia Ventricular Dysfunction trial (REVIVED-BCIS2), percutaneous coronary intervention (PCI) did not. The aim of this study was to explore differences in outcomes of participants treated with medical therapy alone in STICHES vs. REVIVED-BCIS2 and to assess the incremental benefit of CABG or PCI. METHODS: Pooled analysis of adjusted individual participant data from two multicentre randomized trials. All patients had left ventricular ejection fraction ≤35% and coronary artery disease and received medical therapy. Participants were randomized 1:1 to CABG (STICHES) or PCI (REVIVED-BCIS2). The primary outcome was the composite of all-cause death and hospitalization for heart failure over all available follow-up. RESULTS: A total of 1912 participants (88% male, 76% white ethnicity) were included with 98.3% completeness of follow-up for the primary outcome. The median follow-up was 118 months in STICHES and 41 months in REVIVED-BCIS2. Those receiving medical therapy alone in REVIVED-BCIS2 had fewer primary outcome events than those receiving medical therapy alone in STICHES (adjusted hazard ratio 0.60, 95% confidence interval 0.48-0.74, P < .001). Patients receiving PCI in REVIVED-BCIS2 were less likely to experience a primary outcome event than those receiving CABG in STICHES. Adjusted outcomes of patients treated with CABG in STICHES were worse than those receiving medical therapy alone in REVIVED-BCIS2. CONCLUSIONS: Patients with ischaemic cardiomyopathy receiving medical therapy in REVIVED-BCIS2 had better outcomes than those in STICHES, with or without CABG surgery. Further trials comparing CABG, PCI, and medical therapy in this population are warranted.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Ryan M, Petrie MC, Kontopantelis E, et al. Medical therapy and outcomes in REVIVED-BCIS2 and STICHES: an individual patient data analysis. Eur Heart J. 2025. PMID: 40048661. doi:10.1093/eurheartj/ehaf080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。